Attached files
| file | filename |
|---|---|
| EX-99.1 - INVESTOR PRESENTATION - ENDRA Life Sciences Inc. | ndra_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of
report (Date of earliest event reported): June 1, 2017
|
ENDRA
Life Sciences Inc.
|
|
(Exact
name of registrant as specified in its charter)
|
|
Delaware
|
|
001-37969
|
|
26-0579295
|
|
(State
or other jurisdiction of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer Identification
No.)
|
|
3600 Green Court, Suite 350, Ann Arbor, MI
|
|
48105
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(Registrant’s
telephone number, including area code): (734) 335-0468
Not Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General
Instruction A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth
company ☑
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On June
1, 2017, ENDRA Life Sciences Inc. (the “Company”)
posted presentation materials (the “Investor
Presentation”) to the investor relations section of the
Company’s website at http://www.endrainc.com. The investor
relations section of the Company’s website contains
additional information that may be of interest to investors. The
Investor Presentation is also furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
The
information in this Current Report on Form 8-K and Exhibit 99.1
attached hereto is intended to be furnished and shall not be deemed
“filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as
expressly set forth by specific reference in such
filing.
9.01.
Financial Statements and Exhibits.
The
exhibits required to be filed as a part of this Current Report on
Form 8-K are listed in the Exhibit Index attached hereto and
incorporated herein by reference.
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
ENDRA Life Sciences Inc.
|
|
|
|
Date:
June 2, 2017
|
By:
|
/s/
Francois Michelon
|
|
|
|
Name:
|
Francois
Michelon
|
|
|
|
Title:
|
Chief
Executive Officer and Director
|
|
3
EXHIBIT
INDEX
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
ENDRA
Life Sciences Inc. Investor Presentation, dated June 1, 2017,
furnished herewith.
|
4